Categories
Posts
- IN3BIO gains approval for Phase I/II clinical trial
- Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells
- Pangaea Oncology Signs 1.1 Mln contract with In3BIO
- Anti-IN01 antibodies significantly improve the activity of RET, BRAF, MEK and PI3K kinase inhibitors in preclinical models
- Anti-EGF antibodies generated by vaccination significantly improve the activity of kinase inhibitors in preclinical models
- Anti-EGF antibodies increase the effect of ALK and MEK inhibitors in ALK and KRAS NSCLC and CRC cell lines
- Antitumor effects of anti-EGF antibodies generated by vaccination in NSCLC tumor cells
- Anti–Epidermal Growth Factor vaccine antibodies enhance the efficacy of tyrosine kinase inhibitors and delay the emergence of resistance in EGFR mutant lung cancer cells
- The effect of EGF-Pathway Targeted Immunization (EGF-PTI) on STAT3 and cancer stem cells in EGFR mutant NSCLC cells
- Pathway Targeted Immunotherapy: Rationale and evidence of durable clinical responses with a novel, EGF-directed agent for advanced NSCLC
